Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | CIT | O14578 | 16/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009331 | 0.89 | CIT (0.58) | JAK1CITIKBKBCHUK | |
| SCHEMBL30008944 | 0.87 | JAK1 (0.62) | JAK1CITNEK1 | |
| SCHEMBL30009446 | 0.82 | JAK1 (0.61) | JAK1CITIKBKBCHUKLMNA | |
| SCHEMBL30009459 | 0.77 | CIT (0.64) | JAK1CIT | |
| SCHEMBL30355935 | 0.76 | JAK1 (0.83) | JAK1 | |
| SCHEMBL20919022 | 0.76 | JAK1 (0.83) | JAK1 | |
| SCHEMBL30009899 | 0.75 | JAK1 (0.59) | JAK1CITIKBKBCHUK | |
| SCHEMBL1718374 | 0.74 | CIT (0.71) | CITIKBKBCHUK | |
| SCHEMBL30009109 | 0.74 | IKBKB (0.57) | CITIKBKBCHUKNEK1 | |
| SCHEMBL30009376 | 0.74 | IKBKB (0.70) | CITIKBKBCHUKNEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885CIT 417/4885IKBKB 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.